Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The myometrial smooth muscle cell contraction pathway governs the contractile activity of the uterus, particularly relevant during labor. It involves a cascade of events starting with membrane depolarization, calcium influx through voltage-gated channels, activation of myosin light chain kinase (MLCK), and phosphorylation of myosin light chain (MLC20), leading to actin-myosin crossbridge cycling and muscle contraction. Key regulators include oxytocin, progesterone, estrogen, and nitric oxide. Disruption can lead to preterm labor or dysfunctional labor patterns.
Varies depending on the drug; examples include: Oxytocin receptor agonism (oxytocin), Calcium channel blockade (nifedipine), Myosin light chain kinase inhibition, Rho Kinase (ROCK) inhibition
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myometrial Smooth Muscle Cell Contraction Pathway.